Patents Assigned to INIMMUNE CORPORATION
  • Patent number: 11911472
    Abstract: Described here is a method for reducing or preventing Pseudomonas aeruginosa biofilm formation in a human subject in need thereof, comprising administering to the human subject a first composition comprising (a) an antigen-binding polypeptide that binds Pf-family bacteriophage, or (b) a vaccine against Pf-family bacteriophage. Also described is an antigen-binding polypeptide that binds specifically to a CoaB protein of Pf-family bacteriophage or fragment thereof.
    Type: Grant
    Filed: October 8, 2020
    Date of Patent: February 27, 2024
    Assignee: INIMMUNE CORPORATION
    Inventors: Paul L. Bollyky, William Parks, Patrick Secor
  • Patent number: 11458151
    Abstract: Toll-like receptor (TLR) ligands having an allose-based core are stable in aqueous formulation and are useful in treating, preventing, or reducing susceptibility to diseases or conditions mediated by TLRs, such as cancer, infectious disease, allergy, autoimmune disease, sepsis, and ischemia reperfusion.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: October 4, 2022
    Assignee: INIMMUNE CORPORATION
    Inventors: Helene Bazin-Lee, George Ettenger, Juhienah Khalaf, Kendal T. Ryter
  • Patent number: 10835607
    Abstract: Described here is a method for reducing or preventing Pseudomonas aeruginosa biofilm formation in a human subject in need thereof, comprising administering to the human subject a first composition comprising (a) an antigen-binding polypeptide that binds Pf-family bacteriophage, or (b) a vaccine against Pf-family bacteriophage. Also described is an antigen-binding polypeptide that binds specifically to a CoaB protein of Pf-family bacteriophage or fragment thereof.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: November 17, 2020
    Assignee: INIMMUNE CORPORATION
    Inventors: Paul L. Bollyky, William Parks, Patrick Secor